Featured News

Fundraising Initiatives

2017 Walk to Answer TTP Together

On Saturday, September 16, 2017, one hundred and fifty registered participants took part in the 7th annual Walk to Answer TTP Together. Participants walked internationally, in their local communities to help raise life-saving awareness and funds for TTP!

Positive topline results from the Phase III HERCULES study with caplacizumab

October 2, 2017 ABLYNX "announced positive topline results from the Phase III HERCULES study with caplacizumab, the Company's anti-von Willebrand factor (vWF) Nanobody® being developed for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP)." View the full article.